Evidence map›Paper›PMID 28176205›Full record

ArticleFamilial cancer2017

Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.

Mohammad R Akbari, Shiyu Zhang, Deborah Cragun, Ji-Hyun Lee, Domenico Coppola, John McLaughlin, Harvey A Risch, Barry Rosen, Patricia Shaw, Thomas A Sellers and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Ovarian Cancer Prevention in High-risk Women.Clinical obstetrics and gynecology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Mohammad R AkbariWomen's College Research Institute, Women's College Hospital, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada.
Shiyu ZhangWomen's College Research Institute, Women's College Hospital, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada.
Deborah CragunDepartments of Cancer Epidemiology, Moffitt Cancer Center, Biostatistics, Anatomic Pathology, and Experimental Therapeutics, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Ji-Hyun LeeDepartments of Cancer Epidemiology, Moffitt Cancer Center, Biostatistics, Anatomic Pathology, and Experimental Therapeutics, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Domenico CoppolaDepartments of Cancer Epidemiology, Moffitt Cancer Center, Biostatistics, Anatomic Pathology, and Experimental Therapeutics, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
John McLaughlinSamuel Lunenfeld Research Institute, and Dalla Lana School of Public Health, University of Toronto, 600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, 60 College St., New Haven, CT, 06510, USA.
Barry RosenDepartment of Gynecology-Oncology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, ON, M5T 2M9, Canada.
Patricia ShawDepartment of Pathology, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5T 2M9, Canada.
Thomas A SellersDepartments of Cancer Epidemiology, Moffitt Cancer Center, Biostatistics, Anatomic Pathology, and Experimental Therapeutics, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Joellen SchildkrautDepartment of Community and Family Medicine, Duke Comprehensive Cancer Center, Duke University Medical Center, Box 2949, Durham, NC, 27710, USA.
Steven A NarodWomen's College Research Institute, Women's College Hospital, University of Toronto, 790 Bay Street, 7th Floor, Toronto, ON, M5G 1N8, Canada. steven.narod@wchospital.ca.
Tuya PalDepartments of Cancer Epidemiology, Moffitt Cancer Center, Biostatistics, Anatomic Pathology, and Experimental Therapeutics, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
Moffitt Cancer Center · USUniversity of Toronto · CAWomen's College Hospital · CADuke Medical Center · USPrincess Margaret Cancer Centre · CAYale University · US

Funding

Ovarian Cancer and Mismatch Repair DeficiencyR01CA111914 · NCI · H. LEE MOFFITT CANCER CTR &RES INST · PI PAL, TUYA · 2005 to 2009
$2.2M
Clinical Relevance of Mismatch Repair in Ovarian CancerK07CA108987 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PAL, TUYA · 2006 to 2010
$664k
RISK FACTOR ANALYSIS OF BRCA1 AND BRCA2 CARRIERSR01CA063678 · NCI · UNIVERSITY OF TORONTO · PI NAROD, STEVEN A · 1994 to 1999
–
GENETIC/EPIDEMIOLOGY STUDY OF EPITHELIAL OVARIAN TUMORSR01CA063682 · NCI · YALE UNIVERSITY · PI RISCH, HARVEY A · 1994 to 1998
–
NCI NIH HHS K07 CA108987NCI NIH HHS R01 CA063678NCI NIH HHS R01 CA063682NCI NIH HHS R01 CA111914
6 · The paper itself

Abstract

A high proportion of ovarian cancers from women who carry germline mutations in mismatch repair (MMR) genes demonstrate microsatellite instability (MSI). The utility of pre-screening ovarian cancer specimens for MSI to identify potential patients for germline screening for MMR mutations is uncertain. 656 women with malignant ovarian cancer underwent both MSI testing and germline mutation testing for large rearrangements in three MMR genes, MLH1, MSH2 and MSH6. Germline DNA sequencing data for the same genes was available. Among the 656 women, only four (0.6%) carried a clearly pathogenic MMR mutation. All four cancers from patients with mutations had loss of two or more microsatellite markers (MSI-high). Eighty-four of 652 (13.0%) women without a mutation had MSI-high ovarian cancers. Using MSI-high as a prescreening criterion, the sensitivity of MSI testing to identify germline MMR gene mutations was 100% and the positive predictive value was 4.5%. Germline mutations in MLH1, MSH2 and MSH6 are rare among unselected cases of ovarian cancer. Patients with germline mutations often will have MSI-positive cancers and pre-screening of ovarian cancer specimens may be an efficient way of identifying patients with Lynch syndrome.

Indexed as

Biomarkers, TumorCarcinoma, Ovarian EpithelialDNA-Binding ProteinsDNA Mismatch RepairFemaleGerm-Line MutationHumansMicrosatellite InstabilityMiddle AgedMutL Protein Homolog 1MutS Homolog 2 ProteinNeoplasms, Glandular and EpithelialOvarian NeoplasmsSensitivity and SpecificityBiomarkers, TumorDNA-Binding ProteinsG-T mismatch-binding proteinMLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinMicrosatellite InstabilityOvarian cancer

Identifiers

PMID28176205
OpenAlexW2587463960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.